According to the first real-world analysis of protection against serious sickness with the novel strain in South Africa, two doses of the BioNTech/Pfizer vaccine provide 70% protection against being admitted to hospital with the Omicron coronavirus variant.
However, the defence provided against Omicron is less than the 93% protection
